Log in

Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 NeuralstemGene BiotherapeuticsInnate PharmaMymeticsOmni Bio Pharmaceutical
SymbolNASDAQ:CUROTCMKTS:CRXMNASDAQ:IPHAOTCMKTS:MYMXOTCMKTS:OMBP
Price Information
Current Price$0.88$0.08$6.39$0.05$0.00
52 Week RangeN/AN/ABuyN/AN/A
Beat the Market™ Rank
Overall Score0.80.71.20.70.6
Analysis Score0.00.03.50.00.0
Community Score2.52.42.52.33.1
Dividend Score0.00.00.00.00.0
Ownership Score1.01.00.01.00.0
Earnings & Valuation Score0.60.00.00.00.0
Analyst Ratings
Consensus RecommendationN/AN/ABuyN/AN/A
Consensus Price TargetN/AN/A$9.00N/AN/A
% Upside from Price TargetN/AN/A40.85% upsideN/AN/A
Trade Information
Market Cap$1.87 million$1.30 millionN/AN/AN/A
Beta1.811.32N/A-0.16-27.87
Average Volume1,978,00010,32525,901116,1881,750
Sales & Book Value
Annual Revenue$260,000.00N/A$96.12 million$730,000.00N/A
Price / Sales7.09N/A5.09N/AN/A
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/AN/AN/A
Book Value$6.64 per shareN/A$3.18 per share($0.18) per shareN/A
Price / Book0.13N/A2.01N/AN/A
Profitability
Net Income$-4,930,000.00N/A$-23,250,000.00$-4,690,000.00N/A
EPSN/AN/A($0.34)N/AN/A
Trailing P/E Ratio0.000.00N/A0.000.00
Forward P/E Ratio∞∞N/A∞∞
P/E GrowthN/AN/AN/AN/AN/A
Net Margins-39,417.64%N/AN/A-613.29%N/A
Return on Equity (ROE)-170.51%N/AN/AN/AN/A
Return on Assets (ROA)-110.16%N/AN/A-54.56%N/A
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/AN/A0.08%N/AN/A
Current Ratio2.53%N/A1.95%0.01%N/A
Quick Ratio2.53%N/A1.95%0.01%N/A
Ownership Information
Institutional Ownership Percentage38.30%N/AN/AN/AN/A
Insider Ownership Percentage5.38%49.80%N/A54.18%N/A
Miscellaneous
Employees6620081
Shares Outstanding2.10 million14.49 million76.54 millionN/AN/A
Next Earnings DateN/AN/AN/A8/11/2020 (Estimated)N/A
OptionableOptionableNot OptionableNot OptionableNot OptionableNot Optionable
Comparison Ideas:
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.